Evidence map›Paper›PMID 25118843›Full record

ReviewDer Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft2014

[Multiple sclerosis : rehabilitation and long-term course].

S Beer, J Kesselring

Abstract readEnglish AbstractReview
PubMed Publisher
In one paragraph

Review in Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 5 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

S BeerKlinik für Neurologie und Neurorehabilitation, Rehabilitationszentrum, 7317, Valens, Schweiz, s.beer@klinik-valens.ch.
J Kesselring
Valens Clinics · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMultiple sclerosis (MS) is a highly complex disabling disease with variable pathology and clinical course. Progressive multisystemic involvement of the central nervous system leads to complex functional disturbances and disabilities. Despite disease-modifying therapies and pharmacological symptomatic treatment, the majority of MS patients develop progressive impairments in functions, activities and quality of life in the long-term. Rehabilitation interventions aim at improving symptoms and functional deficits and reducing the negative impact on activities and social participation.

objectivesTo evaluate the impact and value of rehabilitation interventions in MS.

methodsSpecific literature search in PubMed.

resultsGood evidence exists for a positive effect of various rehabilitation interventions and multidisciplinary programs. Long-term prognosis is very variable and depends on various influencing factors. Due to an often unpredictable change of disease activity and the high variability, accurate prediction of long-term prognosis in individual MS cases is still challenging.

conclusionRehabilitation measures should be considered in an early phase of the disease for maintaining functional abilities and reducing the risk of progression of disabilities. Assignment to specific interventions and setting of rehabilitation depend on disease-specific and personal factors and specific goals. Monosyndromic or oligosyndromic impairments in the early phases of the disease can be approached by targeted monodisciplinary ambulatory interventions, whereas more severe and complex disabilities generally necessitate a more intensive multidisciplinary rehabilitation.

Indexed as

HumansMultiple SclerosisOptic NeuritisVision Disorders

Identifiers

PMID25118843
OpenAlexW2399239526

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.